Companies › Shanghai World Leader Pharmaceutical
1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Semaglutide (WL1006) Glucagon-like peptide 1 receptor agonist | GLP1R | Phase 1 | Overweight | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07465965 | Semaglutide (WL1006) | Phase 1 | Overweight | Metabolic and endocrine | Aug 2026 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.